Schizophrenia and macroprolactinoma: Is there a deep link?

Bamarinejad, Atefeh; Nasiri, Shidrokh; Bamarinejad, Fatemeh; Salehidoost, Rezvan; Zare-Farashbandi, Elahe

Schizophrenia and macroprolactinoma: Is there a deep link?

Document Type : CASE REPORT

Authors

¹ Isfahan Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

² Clinical Informationist Research Group, Health Information Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Prolactinomas are the most common type of functional pituitary tumors. Dopamine agonists is the most important drugs used in prolactinoma,have antagonistic effect with antipsychotic drugs used in schizophrenia. Conversely, dopamine antagonist drugs increase prolactin in patients with simultaneous schizophrenia. In the present case, we report a 29-year-old single male with schizophrenia who treated for 8 years with risperidone and presented with macroprolactinoma. Iatrogenic hyperprolactinemia is a well-known side effect of dopamine antagonist drugs for treatment in a patient with schizophrenia. On the other hand, it appears these drugs have the other side effects, such as drug- induced prolactinoma or boost growth.

Keywords

References

1.	Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, et al. Diagnosis and treatment of hyperprolactinemia: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011;96:273-88.
2.	Day PF, Loto MG, Glerean M, Picasso MF, Lovazzano S, Giunta DH. Incidence and prevalence of clinically relevant pituitary adenomas: Retrospective cohort study in a Health Management Organization in Buenos Aires, Argentina. Arch Endocrinol Metab 2016;60:554-61.
3.	Allard L, Albarel F, Bertherat J, Caron P, Christine CR, Carine C, et al. Efficacy and safety of dopamine agonists in psychiatric patients treated with antipsychotics and presenting a macroprolactinoma. Eur Cong Endocrinol 2019;63:288.
4.	Inoue A, Miki S, Seto M, Kikuchi T, Morita S, Ueda H, et al. Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum. Eur J Pharmacol 1997;321:105-11.
5.	Green MF, Horan WP, Lee J. Social cognition in schizophrenia. Nat Rev Neurosci 2015;16:620-31.
6.	Mah PM, Webster J. Hyperprolactinemia: Etiology, diagnosis, and management. Semin Reprod Med 2002;20:365-74.
7.	Ben-Jonathan N, Hnasko R. Dopamine as a prolactin (PRL) inhibitor. Endocr Rev 2001;22:724-63.
8.	Asa SL, Kelly MA, Grandy DK, Low MJ. Pituitary lactotroph adenomas develop after prolonged lactotroph hyperplasia in dopamine D2 receptor-deficient mice. Endocrinology 1999;140:5348-55.
9.	Akkaya C, Kaya B, Kotan Z, Sarandol A, Ersoy C, Kirli S. Hyperprolactinemia and possibly related development of prolactinoma during amisulpride treatment; three cases. J Psychopharmacol 2009;23:723-6.

Advanced Biomedical Research